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 Abstract 
Alzheimer’s disease (AD) is the most common type of dementia observed in the elderly. The 
symptoms of the disease are provoked by neuronal loss caused by neurofibrillary tangles and 
amyloid plaques. The molecular processes that underlie AD’s pathology are at this day not well 
understood. Amyloid β peptide (Aβ) appears to be one of the causes of neuronal toxicity. 42-
residue A (Aβ42) forms insoluble oligomers and fibrils which seem to be one of the leading 
causes of AD.  To study the different molecular processes behind aggregation, toxicity and 
cellular uptake of Aβ42, monomer purification and labeling with a fluorescent dye are crucial. 
More successful fluorescent labeling without disrupting the structure and aggregation of Aβ, 
would increase accuracy and reliability of a wide variety of cellular studies. 
This study aims to improve the protocol for monomer purification and labeling. Aβ with an 
introduced Cys for labeling (A MC1-42) was labeled with ATTO Oxa11 (ATTO-TEC) dye to a 
degree of labeling between 11 and 13%. Different conditions were explored and the labeling was 
most successful with 7 M guanidinium hydrochloride buffer, pH 8 and an incubation time of 3 
hours. The labeled Aβ (MC1-42), that had been purified under sterile conditions, was added to 
HEK 293 cells at three different concentrations and studied under the confocal microscope. Aβ is 
visible in the cells, which suggests that the peptide was internalized and/or interacting with the 
plasma membrane.  
Thioflavin T (ThT) and pentameric formyl thiophene acetic acid (pFTAA) assays were performed 
to study the aggregation kinetics of labeled Aβ (MC1-42) compared to wild-type Aβ42 and 
unlabeled Aβ (MC1-42). The assays showed a lower fibrillation rate for Aβ (MC1-42), both 
labeled and unlabeled. The ThT assay showed that addition of dye seemed to give a slightly 
lower fibrillation rate, which could mean that the dye interferes with the assay. The pFTAA 
assay didn’t show any signal for Aβ (MC1-42), and needs therefore to be rerun with more 
controls before any conclusion could be drawn. 
A preliminary experiment was carried out, in which labeled Aβ42 at a concentration of 2.1 μM 
was added to human CHME3 microglial cells and studied under the confocal microscope. Aβ 
seemed to be internalized by the cells.   
These findings provide a promising point of entry for further research on A42 labeling 
techniques and cellular studies. 
Keywords: Alzheimer’s disease, Amyloid-beta, fluorescence, cellular uptake, labeling 
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Introduction 
Alzheimer’s disease 
Alzheimer’s disease (AD) is a neurodegenerative disorder and is the most common type of 
dementia in the elderly (Purves et al., 2012). At an early stage it causes memory impairment, and 
with the progression of the disease long term memory and other cognitive functions are affected. 
The only certain way to diagnose AD is brain histology, which is obviously only possible to 
carry out post-mortem. The most common histological signs seen in the AD brain are the loss of 
neurons, the presence of neurofibrillary tangles and the formation of amyloid plaques. These 
signs are mostly found in the limbic structures, neocortex and basal forebrain nuclei (Purves et 
al., 2012). 
The molecular causes of AD are presently not well understood, and there is a pressure to find 
better ways to study these molecular processes (Dunning et al., 2016). 
 
Amyloid β peptide (A) 
The Aβ peptide is generated from the amyloid β precursor proteins (APP), which is a membrane 
protein important for membrane transduction (Finder and Glockshuber, 2007). APP can be 
cleaved by different enzymes, called secretases. By which secretases APP is cleaved decide if the 
protein will take the non-amyloidogenic or the amyloidogenic pathway. If it is cleaved by α and 
γ secretases it will follow the non-amyloiddogenic pathway, whereas if it is cleaved by β and γ 
secretases it will generate A and take the amyloidogenic pathway (Cappai and White, 1999).  
 
Amyloid β (Aβ) peptides accumulate in amyloid plaques, which are the last stage of Aβ 
aggregation and are formed by insoluble fibrils (Finder and Glockshuber, 2007).  
The amyloid cascade hypothesis suggests that the aggregation of Aβ is one of the causes of the 
pathology of AD (Finder and Glockshuber, 2007). 
In the brain Aβ can be found in both soluble and insoluble forms, which have different secondary 
structures. In fact, in the soluble form it has a structure rich in random coils, while the insoluble 
form, which is the main cause of fibril formation, has a structure rich in β-sheets (Cappai and 
White, 1999).  Aβ39 keeps its random coil structure at a physiological pH, while Aβ42 rapidly 
converts to β-sheets (Finder and Glockshuber, 2007). 
 
The aggregates formed by Aβ have a high molecular weight (Cohen et al, 2015) and have a high 
percentage of β sheets; the tertiary structure is unique for this kind of fibrils because of the β-
cross conformation, and this is true for all amyloid forming proteins (Ow and Dunstan, 2014)  
 
Plasmids used 
The peptides that were used were wild-type Aβ42 and Aβ (MC1-42) from plasmids provided by 
Sara Linse. The sequences can be found in Table 1. 
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Table 1. Amino acid sequences of the peptides used. 
 
 
Fibril Formation and aggregation 
The aggregation of Aβ is a catalytic cycle with 3 different steps. It starts with primary nucleation, 
which is a slow process when monomers form new oligomers; this is followed by elongation step 
where the fibrils get longer. An additional step is the secondary nucleation, in which oligomer 
formation is catalyzed by the interactions of fibrillar surfaces and A monomers (Cohen et 
al,2015). 
 
Cell toxicity 
The processes underlying Aβ cell toxicity are not clear, but the peptide can interact with many 
vital processes of the cells (Cappai and White, 1999), and it can interact with the surface 
receptors in neurons, such as NMDA, AMPA and nicotinic receptors (Masters and Selkoe, 2012) 
and interfere with their functions. It has been believed for a long time that the plaques were the 
main cause of the toxicity, but recent studies indicate that it is the pre-fibrillary oligomers formed 
during the secondary nucleation that are cause of loss of neurons (Cohen et al, 2015). 
 
Methods 
Several different methods were used this project to purify and study the behavior of Aβ42. 
Size exclusion chromatography (SEC) was used to separate the oligomers and monomers of the 
protein, so pure monomers could be used in cellular experiments. 
For the labeling of Aβ (MC1-42), ATTO Oxa11 was used because it is a maleimide dye and it 
reacts with the Cys thiol group.  
At the beginning of the project and after successful labeling, aggregation kinetics assays were 
also used to observe if there were differences in fibrillation rate between different Aβ42 samples. 
Two different assays were used: Thioflavin-T (ThT) assay and pentameric formyl thiophene 
acetic acid (pFTAA) assay. 
 
ThT assay 
ThT is benthiazole dye that binds to β-sheets. It has a weak fluorescence even when β-sheets are  
not present but the fluorescence increases when bound to β-sheets as a result of fibril formation, 
which makes this a good assay to detect fibril formation over time (Nasir et al, 2015).  
 
p-FTAA assay 
pFTAA seems to bind to a different structural motif than ThT and it is used to detect other 
intermediates during fibrillation. The dye interacts and binds to non-thioflavinophilic aggregates 
during the lag-phase which results in a different curve than in a ThT assay. It also has target-
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dependent fluorescence signal because the dye’s backbone is rigid and causes very specific 
interactions with the fibrils (Åslund et al, 2009). 
 
 
Aim of this study 
The aim of this study was to improve Aβ monomer purification and labeling protocols in use. 
The labeling of Aβ, without changing its structure and aggregation properties, is important for a 
wide variety of cellular studies, e.g. about cellular uptake, toxicity, how the peptide interacts 
with the blood-brain-barrier, and how it is internalized and degraded by microglial cells 
(Jungbauer et al, 2009).   
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Material and Methods 
Protein expression  
Medium was prepared by adding ampicillin and chloramphenicol to autoclaved Luria broth (LB) 
medium to final concentrations of 50 µg/ml and 34 µg/ml, respectively. Start cultures containing 
50 ml medium were inoculated with a 500 µl glycerol stock of BL21*pLysS cells and then 
incubated overnight at 37 °C while shaking. 
8 ml of starting cultures were transferred to 800 ml LB medium and incubated with shaking at 31 
°C until an OD600 between 0.6 and 0.9 was reached. 
Induction of protein expression was achieved by adding 0.5 mM isopropyl β-D1-
thiogalactopyranosid (IPTG) and then the cultures were incubated overnight at 21 °C. 
The cells were harvested in the next morning by centrifugation at 7200xg for 30 minutes, 
discarding the supernatant and resuspending the pellet in 30 ml of 100 mM Tris-HCl, 10 mM 
ethylenediaminetetraacetic acid (EDTA), pH8. The cells were then stored at -20 °C. 
 
Purification of wild-type (WT) Aβ42 and Aβ (MC1-42) 
Frozen cell pellets from starting culture were thawed and sonicated for 3 minutes (2 seconds on 
and 2 off at 65% amplitude). The lysed cells were then centrifuged at 24000xg for 10 minutes at 
4 °C. The supernatant was discarded and the pellet was resuspended in 10 mM Tris-HCl, 1 mM 
EDTA, with 1 mM dithiotreithol (DTT) when Aβ (MC1-42) was purified, pH 8. The suspended 
pellet was then sonicated and centrifuged again as described above. 
 The pellet was dissolved with a homogenizer in 8 M Urea in 10 mM Tris-HCl, 1mM EDTA pH 
8, and was then diluted to 2 M Urea. DEAE sepharose was washed in a Büchner funnel with 
water and 10 mM Tris-HCl, 1 mM EDTA, (1 mM DTT, if Aβ (MC1-42) was purified), pH 8 
buffer, then added to the 2 M Urea solution and incubated it at 4 ° C for 30 minutes with a 
magnetic stirrer. 
The solution was then filtered through a Büchner funnel with filter paper and washed with 10 
mM Tris-HCl, 1 mM EDTA, (1mM DTT for Aβ (MC1-42)) pH 8, and 10 mM Tris-HCl, 1 mM 
EDTA, (1mM DTT for Aβ (MC1-42)), 25 mM NaCl, pH 8. The protein was then eluted with 10 
mM Tris-HCl, 1 mM EDTA, 125 mM NaCl pH 8.  
The eluate was run through a 30 kDa Vivaspin concentration tube at 4500xg at 4 °C. The flow 
through was concentrated using a 5 kDa Vivaspin concentration tube at 4500xg at 4 °C until the 
desired concentration is reached. 
1 ml aliquots of purified Aβ at 20 µM concentration were made and lyophilized in low binding 
tubes in the Speedvac overnight. 
The lyophilized Aβ was then stored at -20 °C until further use. 
13 
 
 
SDS PAGE 
16.5 % Tris-Tricine gels were prepared as specified by the Laemmli SDS PAGE protocol.  
The samples were prepared by using a reducing and non-reducing buffer with or without 
mercaptoethanol and boiled on a heating block at 96 °C. 
The samples and the marker (Page Ruler Plus Prest (Thermo) in Figure 1, and SeeBlue Plus2 
(Thermo) in Figures 3 and 9 were loaded and the gel was run at 50 V for 20 minutes and then 
increased to 150 V for 75 minutes. The gel was then stained with Coomassie for 1 hour at room 
temperature on a shaker and destained in hot water for 1 hour. 
 
Size exclusion chromatography (SEC) 
WT Aβ42 and Aβ (MC1-42) were dissolved in 550 µl 7 M guanidinium hydrochloride (Gu-HCl) 
pH 7 and tris(2-carboxyethyl)phosphine (TCEP) was added to a final concentration of 10 mM or 
1 mM (Table 2). The absorbance was measured in a spectrophotometer to calculate the 
concentration of the sample. A Superdex 75PG column was equilibrated with 20 mM sodium 
phosphate (NaPi), 1 mM EDTA, 0.2 % sodium azide (NaN3) and the sample was then injected 
via a 500 µl loop. The separation was carried out at a flow rate of 0.7 ml/min. The protein 
monomers were collected in fractions of 0.4 ml. The fractions from the monomer peak, that 
elutes at a volume of 17 ml, were mixed in a low binding tube; the concentration was calculated 
by peak integration. 500 µl aliquots were made in low binding tubes and stored at -20 °C. 
 
Aggregation kinetics 
ThT assay 
Samples for the ThT assay were prepared in low binding tubes on ice to prevent fibril formation. 
The total sample volume was 350 µl for 4 replicates. The amount of protein needed to get 3 µM 
concentration was calculated and added in the respective tubes. ThT, from a 1 mM stock 
solution, was added to the protein to a final concentration of 10 µM (3.5 µl). 20 mM NaPi pH 8 
buffer was added to get to 350 µl volume. The tubes were then vortexed shortly and centrifuged. 
80 µl were used for each replicate per well of a black half-width 96 wells plate with transparent 
bottom (Cornig 3881). 
For the ThT assay shown in Figure 9, a stock solution of ATTO Oxa11 (ATTO-TEC) was added 
to the samples. The stock solution was made by dissolving 36 µg dried ATTO Oxa11 (ATTO-
TEC) in 5 µl acetonitrile, adding 6.5 µl of 76.47 mM mercaptoethylamine (MEA) and adjusting 
the final volume to 3 ml with 20 mM NaPi buffer. 12.8 µl of stock dye solution were added to 
the control samples.  
The fibrillation was observed by following the increase in fluorescence over time at 37 ° C 
without shaking, bottom optic and 300 seconds between each time point for at least 16 hours. 
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pFTAA assay 
A master mix for 4 replicates for the pFTAA assay were prepared in low binding tubes on ice to 
prevent fibrillation. The amount of Aβ needed to get a final concentration of 3 µM and the 
amount of pFTAA, froma 15 µM stock solution, to get a concentration of 0.3 µM (7 µl) was 
added to the respective master mix. 20 mM NaPi pH 8 buffer was added to the master mix to the 
final volume of 350 µl. 80 µl of the master mix was used for each well in a black half-width 96 
wells plate with transparent bottom (Cornig 3881). 
The pFTAA assay was run at 37 ° C with no shaking, bottom optics and 300 seconds between 
each time point. 
 
Labeling 
A Superdex 75PG column was equilibrated with 20 mM NaPi, 1 mM EDTA, 0.2 % NaN3. 
3 tubes or more, depending on the desired concentration, of lyophilized Aβ (MC1-42) were 
dissolved in 550 µl 7 M Gu-HCl in a low binding tube by pipetting and vortexing shortly. TCEP 
was added from a 0.625 M stock to the desired concentration, either 10 mM or 1 mM in our case. 
Previously 1 mg ATTO Oxa11 (ATTO-TEC) was dissolved in 500 μl acetonitrile and aliquots of 
18 µl containing 50 nmol dye were lyophilized in the Speedvac. 
The amount of ATTO Oxa11 (ATTO-TEC) to be used was calculated based on the amount of 
protein used and the desired excess of dye (Table 2). The lyophilized dye was dissolved in 20 µl 
acetonitrile.  
The 20 µl dye were added to the dissolved Aβ (MC1-42), the low binding tube was covered with 
aluminum foil to keep it in the dark and the mixture was incubated under different conditions for 
each attempt (Table 2), with 3 hours at room temperature giving the best results. 
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Table 2. Different conditions used for labeling attempts.  
 
The labeled monomers were collected at the highest peak for ATTO Oxa11 (ATTO-TEC) (Abs 
658, elution volume circa 18-19 ml), fractions of 0.4 ml were taken. The labeled monomers were 
pooled in one low binding tube and 100 µl aliquots prepared and stored at -20 ° C. 
The specific absorbances of the conjugated dye and the protein was calculated from their 
respective monomer peak by peak integration, which gave us the absorbance; this was used to 
calculate the degree of labeling (DOL) by using Equation 1. 
Equation 1. Equation for calculating the degree of labeling. Abs658 is the absorbance at the 
maximum for ATTO Oxa11 dye (ATTO-TEC), Abs280 is the absorbance at the maximum of 
Aβ, ε658 and ε280 are the extinction coefficients of the dye and Aβ, and CF280 is the correction 
factor of the dye absorbance at 280 nm. 
 
 
 
Sterile monomer purification 
A Superdex 75PG column was washed with 70 % ethanol overnight to get sterile conditions. 
Afterwards it was equilibrated with 20 mM NaPi for 1 hour. The pipette tips, low binding tubes, 
96 well plate and buffers used were autoclaved.  
The preparation of the labeled Aβ (MC1-42) was the same as for the non-sterile labeling, as 
described above. In Table 2 the conditions used for attempt 6 (sterile labeling) can be seen. The 
monomer collection and calculations are also described above. 
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Cell cultures 
HEK293 cells were thawed in a 37 ° C water bath. Sterile medium was prepared by adding fetal 
calf serum to DMEM/F12 media + Glutamax (Gibco). Thawed cells were added to 10 ml of 
medium in a T75 culture flask. The medium was changed to fresh, temperated medium after one 
day. The cells were washed with PBS, and 2 ml 1x trypsin was added and incubated for a few 
minutes until the cells detached. Fresh medium was added and the cells were centrifuged at 1000 
rpm for 5 minutes. The supernatant was discarded and the cells were resuspended in 3 ml fresh 
medium. 10 ml of fresh medium and 500 µl of cells were transferred to a new T75 culture flask 
and incubated.  
Chamber slides (NuncTM) were coated with poly-D-lysine and incubated at 37 °C for 5 hours. 
The poly-D-lysine was removed and the chambers were washed with PBS. 500 µl of fresh 
medium were added to each of the 8 chambers and 5 µl of cells, and incubated at 37 °C 
overnight. The medium was gently removed and 100 µl of serum-free medium was added to the 
chambers and in 3 wells labeled Aβ was added (Table 3) at different concentrations.  
 
Table 3. Different volumes of serum free buffer and labeled Aβ (MC1-42), and corresponding Aβ (MC1-
42) concentrations used for the incubation of the cells are shown.  
 
After 5 hours of incubation at 37 °C, cells were washed twice with PBS, and fixed with 4% PFA 
for 15 minutes, followed by additional washing in PBS and the cells were stored in PBS 
overnight at 4 ° C. 
40 μl of DAPI, used to stain the cell nucleus, were added to each chamber, and glass slides were 
put on top and sealed with nail polish.  
 
Microglia experiment 
Human CHME3 microglia cells were provided by Erik Hjorth, NVS department KI, and labeled 
Aβ (MC 1-42) was added to the medium (DMEM/high glucose + glutamax serum free) to a 
concentration of 2.1 µM and incubated for 3 hours at 37 °C. The cells were stained with 
carboxyfluoresceindiacetate (CFSE), which stains cytosolic components and is used to study live 
cells, and scanned in LSM510 confocal microscope.  
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Results 
SDS –PAGE analyses 
Figure 1 shows an SDS PAGE gel analysis of the different purification steps for WT Aβ (Fig 
1A) and Aβ (MC1-42) (Fig 1B).  Aβ42 has a molecular weight of circa 4 kDa and a band at 4 
kDa can be seen at all relevant purification steps.  
In the final elution only the band at 4 kDa should be visible. Figure 1.B shows a few bands 
around 28 kDa, which could mean that there are contaminants still present. 
 
 
Figure 1 16.5% Tris Tricine gels for the different steps of WT Aβ (A) and Aβ (MC1-42) (B) purification.  
In Figure 1.B the bands are very faint because too little protein was loaded on the gel. 
 
Size exclusion chromatography of WT and MC 
SEC was run for WT Aβ, WT Aβ with TCEP, Aβ (MC1-42) and Aβ (MC1-42) with TCEP to see 
if there was a significant difference in the amount of monomers and oligomers. From earlier 
studies we know that the oligomer peak starts around 9 ml and the monomer peak starts at 16 ml. 
Figure 2 shows both peaks where we expected them. There is no significant difference in the size 
of the monomer peak. The oligomer peak shows a slight difference between Aβ WT and Aβ 
(MC1-42), with the peaks for WT Aβ and WT Aβ with TCEP being slightly higher than the 
peaks for Aβ (MC1-42). 
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Figure 2 SEC curves for WT Aβ42, WT Aβ42 with TCEP, Aβ (MC1-42), and Aβ (MC1-42) with TCEP. 
The monomer peak is seen between 16 and 20 ml, and the oligomer peak is seen between 10 and 13 ml 
for all samples. 
 
SDS gel for different fractions  
Monomers and oligomers taken from the fractions during SEC separation (Figure 2) were 
prepared under reducing and non-reducing conditions and loaded on a 16.5 % Tris Tricine gel 
(Figure 3).  
The samples from the oligomer peak show a clear band under reducing conditions (labeled in 
Fig. 3 as WT Aβ42 O R) and a very faint band under non reducing conditions (labeled in Fig. 3 
as WT Aβ42 O NR) at 14-17 kDa. No band can be seen at 4 kDa, which would be where we 
expect the monomer band, which means that no monomers are present. 
In all monomer samples a band at 4 kDa is present under both reducing and non-reducing 
conditions. Under the non-reducing conditions, we would expect bands for dimers because Aβ 
(MC1-42) can form disulphide dependent dimers. Bands at 17 and 14 kDa were seen for all the 
monomer samples, thet are more pronounced under reducing conditions. 
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Figure 3  16.5 % Tris Tricine gel with samples from the SEC purification shown in Figure 2. From the 
left: SeeBlue Plus2 marker, WT Aβ42 reduced oligomer, WT Aβ42 reduced monomer, WT Aβ42 non-
reduced oligomer, WT Aβ42 non-reduced monomer, SeeBlue Plus2 marker, WT Aβ42 reduced 
monomer, WT Aβ42 with TCEP reduced monomer, Aβ (MC1-42) reduced monomer, Aβ (MC1-42) with 
TCEP reduced monomer, WT Aβ42 non-reduced monomer, WT Aβ42 with TCEP non-reduced 
monomer, Aβ (MC1-42) non-reduced monomer, Aβ (MC1-42) with TCEP non-reduced monomer. A 
monomer band at 4 kDa is visible in all samples except the oligomer samples. 
 
Thioflavin-T curve for WT Aβ and Aβ (MC1-42) 
A ThT test was run with the purified monomers shown in Figure 2 to see if TCEP would affect 
the fibril formation and if there is a difference in fibrillation between WT Aβ42 and Aβ (MC1-
42). 
Figure 4 shows how the samples fibrillate during 25 hours. The lag phase is quite similar 
between Aβ (MC1-42) with and without TCEP and WT Aβ42. WT Aβ with TCEP has a longer 
lag phase which means that the fibrillation is delayed. Such a big difference was not expected. 
TCEP is a reducing agent and breaks disulphide bonds. It should however not affect WT Aβ42 
because there are no cysteines in the peptide that could form disulphide bonds. 
Aβ (MC1-42) shows a slightly shorter lag phase which means that it fibrillated faster than WT 
Aβ42 and Aβ (MC1-42) with TCEP. This could be due to the presence of a Cys in Aβ (MC1-42), 
which can form disulphide bonds and thereby create aggregates faster. TCEP seems to affect Aβ 
(MC1-42) and slow down the fibrillation. 
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Figure 4 ThT curves for Aβ (MC1-42). Aβ (MC1-42) with TCEP, WT Aβ42, and WT Aβ42 with TCEP. 
Longer lag phase, suggesting slow fibrillation, is visible for WT Aβ42 with TCEP. 
 
Labeling attempts 
The labeling attempts 1 and 2 in Table 2 did not work and no monomers got labeled. When the 
conditions were changed to the ones seen in attempt 3, we could see that the labeling was 
successful.  The absorbance for the dye, measured at 658 nm, showed an increase to circa 89 
mAU, as can be seen in Figure 5.  
 
 
Figure 5 SEC curve for labeling attempt nr 3 (Table 2). Absorbance curves for both Aβ (MC1-42) at 280 
nm and ATTO Oxa11 (ATTO-TEC) at 658 nm are presented. The monomer peak can be seen for both 
absorbances between 17 ml and 21 ml. 
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The protein concentration (4.4 μM) and the degree of labeling (13 %) were calculated by using 
Equation 1. 
By changing the labeling conditions, we could see a decrease in the protein concentration and 
degree of labeling (Appendix), so when we prepared the sterile labeled Aβ (MC1-42) we used 
the same conditions as in attempt 3.  
Figure 6 shows the SEC curve for the sterile labeling attempt. The monomer peak can be seen at 
both 280 nm and 658 nm between 17 and 21 ml. After calculating the peak area, we calculated 
both protein concentration (7.1 μM) and degree of labeling (12%). 
A peak can be seen after the monomer peak at 21 ml. To be sure that it was not a contaminant a 
sample from it was run on a Tris Tricine gel (Figure 9). 
 
Figure 6 SEC curve for sterile labeling (attempt 6 in Table 2). Curves for both Aβ (MC1-42)’s 
absorbance at 280 nm and ATTO Oxa11 (ATTO-TEC)’s absorbance at 658 nm are present. The monomer 
peak can be seen for both absorbances between 17 ml and 21 ml. 
 
ThT curves for WT Aβ42, Aβ (MC1-42), and labeled Aβ (MC1-42) 
ThT assays were run for WT Aβ 42, Aβ (MC1-42) and labeled Aβ (MC1-42) to see if ATTO 
Oxa11 (ATTO-TEC) affects the fibrillation of the protein. 
Figure 7 shows that labeled Aβ (MC1-42) apparently does not form fibrils. This could mean that 
the dye inhibits fibrillation. The unlabeled Aβ (MC1-42) also seems to have a lower fibrillation 
rate.  
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Figure 7. ThT  curves for WT Aβ42, Aβ (MC1-42), and labeled Aβ (MC1-42). Fibrillation is visible for 
WT Aβ42, and Aβ42 (MC1-42), no fibrilation is seen for labeled Aβ (MC1-42). 
Because of the results seen in Figure 7, we decided to redo the ThT test and include more 
controls. In order to see if the dye has effects on the fibrillation, we added the free dye (12.8 µl) 
to the WT Aβ42 and unlabeled Aβ (MC1-42) ThT master mixes and to the blank.  
The curves for WT Aβ42 with and without dye are as high as we expected and similar to the one 
shown in Figure 8, with the one with the dye being slightly lower.  The pure unlabeled Aβ 
(MC1-42) also shows a curve that is similar to the one that we saw in the previous ThT test, and 
when the dye solution was added the curve was again slightly lower.  
In the second ThT run we see a curve for the labeled Aβ (MC1-42) even if it is lower than the 
other samples. This means that there is fibril formation, although at a lower rate. To be sure that 
it is not the dye that affects the fibrillation we analysed a sample were the labeled Aβ (MC1-42) 
and WT Aβ42 were mixed at a ratio of 1:200 (Nasir et al, 2015). This sample behaves very 
similar to WT Aβ42 with dye present, which means that the dye does not inhibit fibrillation.  
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Figure 8 ThT curves for blank with stock solution of ATTO Oxa11, WT Aβ42, WT Aβ42 with free dye, 
Aβ (MC1-42), Aβ (MC1-42) with free dye, labeled Aβ (MC1-42), and a mixture of labeled Aβ (MC1-42) 
and WT Aβ42 at a ration of 1 :200. Fibrillation is visible for all the samples. 
 
SDS gel for Aβ monomers 
Figure 9 shows different labeled and unlabeled monomer samples from Aβ under reducing and 
non-reducing conditions.  
Samples 1 and 2 in Figure 9 are samples from the protein expression part, before and after 
induction, respectively. Before induction we can see bands for a wide range of proteins, but no 
band can be seen at 4 kDa, but it can be seen after induction, which means that the induction was 
successful and Aβ is expressed.   
Sample 3 is the WT Aβ42 monomer and it shows a clear monomer band at 4 kDa under reducing 
and non-reducing conditions. In the reduced sample a faint band can be seen at 14 kDa, which 
could mean that there was contamination or that the protein has aggregated. Under non-reducing 
conditions we can see clear bands at 14 and 17 kDa, which is expected and shows that the 
protein has aggregated. 
Sample 4 is the collected Aβ (MC1-42) monomer peak. Under reducing and non-reducing 
conditions only the monomer band can be seen at 4 kDa. Under non reducing conditions the 
band is faint, this could be caused by the low amount that was loaded on the gel. No higher mass 
bands are visible.  
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Sample 5 is the labeled monomer peak of Aβ (MC1-42) (Figure 6).  As in sample 4 only the 
monomer band at 4 kDa is visible under reducing and non-reducing conditions. The band is more 
faint, and as in sample 4 it could be caused by a low amount of protein that was loaded on the 
gel. 
Sample 6 is a side fraction of the labeled monomer peak in sample 5. Clear monomer bands can 
be seen under reducing and non-reducing conditions. Under non-reducing conditions faint bands 
at 14-17 kDa can be seen, suggesting protein aggregation.  
Sample 5 and 6, with the labeled Aβ (MC1-42), seems to migrate slower than the wild-type 
peptide, suggesting that the labeled monomers are bigger. 
Sample 7 is from the peak eluting after the labeled monomer peak at 21 ml in Figure 6. No bands 
are visible under reducing or non-reducing conditions which strongly suggests that it was salt 
eluting after the monomer. 
 
Figure 9 Samples 1 and 2 are samples from before and after induction, a monomer band at 4 kDa is 
visible only after induction. Sample 3 is WT Aβ42, sample 4 is Aβ (MC1-42), sample 5 is labeled Aβ 
(MC1-42), sample 6 is the side peak of the labeled Aβ (MC1-42), and sample 7 is salt eluting after the 
labeled monomer. All samples were run under both reduced and non-reduced conditions and monomer 
bands at 4 kDa for all the samples, except sample 7, are visible. 
 
pFTAA curves for WT Aβ42, Aβ (MC1-42), and labeled Aβ (MC1-42) 
pFTAA assays were run to see if it would show different curves for WT Aβ42, pure unlabeled 
Aβ (MC1-42) and labeled Aβ (MC1-42). pFTAA should be more sensitive than ThT, so we 
would expect to be able to detect also intermediates that are low in abundance. 
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Figure 10 shows that the fluorescence increase measured over time at 510 nm and 540 nm are 
almost identical. No fibrillation can be detected for unlabeled and labeled Aβ (MC1-42), this 
could mean that the ATTO Oxa11 (ATTO-TEC) dye interacts with pFTAA. To test this, we 
would need to run a new pFTAA test with the same controls as in Figure 8. 
 
Figure 10 pFTAA fluorescence curves for WT Aβ42, Aβ (MC1-42) and labeled Aβ (MC1-42) for both 
emission wavelengths 510 nm and 540 nm. The curves look almost identical at both wavelengths and 
only show fibrillation for WT Aβ42. 
 
Cell incubation with labeled Aβ (MC1-42) 
Figure 11 shows the nuclei of HEK293 stained with DAPI (blue) and Aβ (MC1-42) labeled with 
ATTO Oxa11 (ATTO-TEC) (red) at concentrations of 4.8 μM (Fig. 11A and B), 2.4 μM (Fig. 12 
C and D), and 0.5 μM (Fig. 11E and F). The labled monomerhad a DOL of 11.56%. 
Figure 11A and B show colocalization of Aβ (MC1-42) (red) and the cell nuclei (blue) at protein 
concentration of 4.8 μM. In Figure 11 B, a red signal is visible around most of the cell nuclei. In 
Figure 11 A the red signal is clearly visible around one nucleus, which could mean the peptide 
was taken up by the cell or that it interacts with the cell surface. 
At protein concentrations of 2.4 μM and 0.5 μM (respectively Figures 11C and D, and 11E and 
F), the red signal is a lot weaker, but single spots where the signal is higher can still be found, for 
example in Fig. 11C and Fig. 11F. 
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Figure 11 Microscopic images of HEK293 cells incubated with labeled Aβ (MC1-42) with different 
concentrations: 4.8 μM (A and B), 2.4 μM (C and D) and 0.5 μM (E and F). The nuclei of the HEK 293 
cells were stained with DAPI, shown in blue. The Aβ (MC1-42) labeled with ATTO Oxa11 (ATTO-TEC) 
is shown in red.  
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Microglia interactions of A 
Figure 12  shows labeled Aβ (MC1-42) and human CHME3 microglia cells. The cells were 
incubated with a 2.1 μM concentration of Aβ (MC1-42) for 3 hours.  Figure 12C could indicate 
that the peptides have been phagocytosed by the cells.   
 
Figure 12 In Fig A, the fluorescence from ATTO Oxa11 (ATTO-TEC) labeled Aβ (MC1-42) is pictured. 
CSFE stained human CHME3 microglia are shown in Fig. B. In Fig C the previous pictures are 
superimposed and seem to colocalize.  
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Discussion  
The aim of this study was to improve the labeling and monomer purification protocol for the Aβ 
(MC1-42) peptide. The amount of labeled Aβ monomers is important for the detection during 
cell experiments, which could facilitate the studies of Aβ toxicity and cellular uptake. 
Labeling 
The dye used to label the peptide in this study was ATTO Oxa11 (ATTO-TEC), which reacts 
with the Cys thiol groups.  
To get a good label degree, the pH of the Gu-HCl was important, in fact when the pH was 7 the 
labeling failed, while when the pH of the buffer was adjusted to 8 we could see an improved 
labeling, with an increased degree of labeling from 4 % in previous studies to 11-13%.   
The amount of dye and TCEP were also changed, but we tried to always have a 5 or 6-fold 
excess of dye compared to the amount of protein. Even when we used a doubled amount of dye 
the labeling results were not better than the ones we got for attempt 3 in Table 2.  
In the first to attempts we used 10 mM concentration of TCEP, which we then calculated was a 
200-fold excess, which could be the reason the first two attempts in Table 2 failed. When we 
lowered the TCEP concentration to 1 mM, the labeling seemed to be more successful.  
In all the SEC curves for the successful labeling attempts we can see that the two curves at 
280nm and 658 nm are not overlapping. This could be caused by the dye interacting with the 
sepharose in the column.  
Aggregation kinetics 
ThT and pFTAA assays were run to make sure that the dye does not affect the fibrillation of the 
peptide. The ThT curves in Figures 4, 7 and 8 show that there may be an interference or that the 
dye could inhibit ThT binding to the peptide. In Figure 4 the curves for WT Aβ42 seem to be 
lower than in Figure 7 and 8. The assays need to be rerun to find possible explanations to this. A 
way to see if the dye affects the ThT binding to the protein would be to look at the fluorescence 
of the labeled fibrils with added ThT to see if there is a superimposition of the dye and ThT.  
The pFTAA assay should also be rerun to see if an increase of fibrillation could be detected for 
labeled and unlabeled Aβ (MC1-42) and more controls similar to the ones used in Figure 8 
should be used to see if the dye interacts with pFTAA and inhibits the detection of fibril 
formation. 
Cell experiments 
Usually for the cell experiments, astrocytes are used; but because no astrocytes were available, 
we used HEK 293 cells. These cells are easy to cultivate and grow fast, but they are kidney cells 
which means that they do not behave as astrocytes and microglia. We did not expect to see 
colocalization with the labeled Aβ and HEK 293 cells, but in Fig 11 it is visible. Some factors 
have to been taken into account: e.g. when a lot of cells cluster together, the labeled protein can 
get caught and give an unspecific signal, which could be the case for some cluster of cells in 
Figure 11, but there are single DAPI stained nuclei, the most obvious one in Fig 11.A, where it 
seems to be a specific signal. Also we cannot deduce from Figure 11 whether it is labeled 
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monomer or free dye that is detected, or whether the labeled peptide has been internalized or if it 
is just unspecifically bound to the plasma membrane.  
When we looked at the cells, we could see that they were dead, probably due to drying during 
fixation and washing, but it could be due to Aβ toxicity. To know what the cause of death was, 
we should have looked at the cells in the microscope after incubation with Aβ (MC1-42) and 
during the fixing steps.  The next step in the study after the confocal experiment would have 
been a toxicity assay.  
Microglia experiments  
The microglia experiment was a pilot study. Colocalization of labeled Aβ with cells could be 
detected, but the signals were far too few to be trustworthy without more data. Because these 
results showed that ATTO Oxa11 (ATTO-TEC) can be detected, and that colocalization is 
visible, further studies should be done with higher concentrations of Aβ and longer incubation 
times. 
 
Future perspectives 
More studies are required to improve the reliability of these findings. There is a need of better 
labeling protocols of Aβ42 to facilitate cellular studies, that can help to understand how the 
molecular processes of the protein affects toxicity, how it is taken up and degraded by microglial 
cells, how the peptide activates macrophages and how it interacts with the blood-brain-barrier, 
for example (Jungbauer et al, 2009). With more knowledge about the molecular processes and 
interactions of Aβ, the hunt for effective therapies against AD may be facilitated. 
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